40
Participants
Start Date
August 31, 1998
Primary Completion Date
June 30, 2000
Study Completion Date
January 31, 2005
irinotecan hydrochloride
One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
Cancer Care Consultants, Las Vegas
Daniel Freeman Memorial Hospital, Inglewood
Office of Marilou Terpenning, Santa Monica
Office of Robert C. Klein, Santa Monica
Cancer Care Associates Medical Group, Torrance
Pacific Shores Medical Group, Long Beach
Valley Hematology and Oncology, West Hills
UCLA Cancer Center - Santa Clarita, Valencia
Los Robles Regional Medical Center, Thousand Oaks
Office of Eddie Hu, M.D., Monterey Park
Wilshire Oncology Medical Center, Pomona
Oncology Medical Center of North County, Vista
St Jude Heritage Health Foundation, Fullerton
Ventura County Hematology-Oncology Medical Group, Inc., Oxnard
Cancer Center of Santa Barbara, Santa Barbara
Sansum Medical Clinic, Santa Barbara
Comprehensive Blood and Cancer Center, Bakersfield
Marian Medical Center, Santa Maria
UCLA - Antelope Valley Cancer Center, Lancaster
Salinas Valley Memorial Hospital, Salinas
Community Hospital of the Monterey Peninsula, Monterey
Office of Jerome L. Rubin, Monterey
James L. Poth, M.D., Michael Alexander, M.D., Inc., Santa Cruz
Dominican and Watsonville Community Hospital, Soquel
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles
Pharmacia and Upjohn
INDUSTRY
Jonsson Comprehensive Cancer Center
OTHER